MOTS-c Peptide Enters Phase 2a Clinical Trials: What the New Human Study Means for Metabolic Research

A significant milestone in peptide science has arrived. MOTS-c, the mitochondrial-derived peptide first identified just over a decade ago, has now entered formal Phase 2a human clinical testing. The trial targets adults with prediabetes and overweight or obesity, marking one of the first serious attempts to translate this naturally occurring mitochondrial signal into a structured clinical program. For researchers, biohackers, and anyone following the evolution of mitochondrial medicine, this development deserves close attention.

What Is MOTS-c?

MOTS-c stands for Mitochondrial Open Reading Frame of the Twelve S rRNA type-c. It is a 16-amino-acid peptide encoded directly within the mitochondrial genome, specifically in the 12S rRNA gene. Unlike most peptides studied in metabolic research, MOTS-c is not a synthetic analog created in a lab. It is a molecule our own mitochondria produce and release under conditions of metabolic stress, acting as an internal communicator between the mitochondria and the rest of the cell.

The discovery was published in 2015 by researchers led by Changhan Lee in the journal Cell Metabolism. They identified MOTS-c while screening for small open reading frames in mitochondrial DNA that could influence metabolism. What emerged was a peptide that appeared to function as a systemic regulator of energy balance, insulin sensitivity, and cellular stress responses. This was groundbreaking because it showed that mitochondria do far more than generate ATP. They also produce bioactive peptides that influence nuclear gene expression and whole-body physiology.

How MOTS-c Works

The mechanism of MOTS-c centers on its ability to translocate from the mitochondria to the cell nucleus when cells experience metabolic challenge. Once in the nucleus, it interacts with transcription factors and chromatin to modulate genes involved in antioxidant defense, mitochondrial biogenesis, and fuel utilization. A core pathway it activates is AMPK, the same energy-sensing kinase turned on by exercise and compounds like metformin. Through AMPK and related routes involving the folate-purine cycle and AICAR accumulation, MOTS-c promotes glucose uptake in skeletal muscle via GLUT4 transporter translocation, enhances fatty acid oxidation, and supports metabolic flexibility.

This is why MOTS-c is often described as an "exercise mimetic." It does not replace the need for physical activity, but it appears to recapitulate many of the molecular benefits that exercise provides at the cellular level. In multiple preclinical models, administration of MOTS-c has produced striking results. Mice fed high-fat diets and treated with the peptide were protected from obesity and insulin resistance. Older mice showed substantial improvements in physical performance, with some studies reporting roughly doubled treadmill running capacity compared with untreated age-matched controls. These benefits extended across different ages, suggesting the peptide can help counteract aspects of age-related metabolic decline.

Human Observational Data

Human observational data has reinforced the preclinical picture. When young, healthy men performed acute exercise on a stationary bike, MOTS-c levels in skeletal muscle increased nearly twelve-fold and remained significantly elevated even after several hours of rest. Circulating levels in plasma also rose noticeably during and after the bout. This exercise-induced surge aligns with the idea that MOTS-c is one of the molecular signals through which physical activity improves metabolic health. At the population level, circulating MOTS-c tends to be lower in older adults, in individuals with higher BMI, and in some groups with insulin resistance or type 2 diabetes. These associations have made the peptide an attractive target for therapeutic exploration.

Until recently, direct human interventional data on native MOTS-c remained limited. An analog called CB4211, developed by CohBar, completed Phase 1 testing in people with obesity and non-alcoholic fatty liver disease. That study demonstrated acceptable safety and tolerability with daily subcutaneous dosing, along with some signals on liver enzymes, but further development of that specific analog was not pursued. The current trial sponsored by Hudson Biotech represents the first substantial controlled evaluation of the native MOTS-c sequence itself in a relevant patient population.

The Phase 2a Trial (NCT07505745)

The study, registered as NCT07505745 on ClinicalTrials.gov, is a Phase 2a, randomized, double-blind, placebo-controlled trial. It is being conducted at Peking University Shenzhen Hospital in China. The design calls for approximately 120 adults aged 18 to 65 with a BMI between 27 and 40 kg/m² and confirmed prediabetes. Prediabetes is defined using standard criteria: HbA1c between 5.7% and 6.4%, fasting plasma glucose 100–125 mg/dL, or 2-hour plasma glucose 140–199 mg/dL during a 75 g oral glucose tolerance test. Participants must have stable body weight and be willing to maintain consistent diet and activity patterns during the study.

Participants receive either MOTS-c or matching placebo via daily subcutaneous injection for 12 weeks, alongside standardized lifestyle counseling. There is a screening period of up to four weeks and a four-week safety follow-up after treatment ends. The primary efficacy endpoint is the change from baseline in insulin sensitivity measured by the Matsuda Index derived from an oral glucose tolerance test at week 12. Safety is assessed through treatment-emergent adverse events up to week 16. Secondary measures include changes in HbA1c, fasting glucose, 2-hour post-OGTT glucose, and immunogenicity testing.

The trial began in early February 2026 and is currently recruiting. Primary completion is estimated for February 2027, with full study completion targeted for mid-2028. Results are therefore still some time away, but the very existence of this well-designed Phase 2a program is meaningful. It validates years of preclinical work and opens the door to larger efficacy trials if the data support further development.

What Positive Results Could Mean

What could positive results mean? For individuals with prediabetes and overweight or obesity who struggle to achieve sufficient physical activity due to joint issues, fatigue, or other limitations, an exercise-mimetic approach could offer metabolic support. The trial is also testing whether MOTS-c can improve cardiometabolic risk markers beyond insulin sensitivity alone. Because the peptide works through AMPK and mitochondrial signaling pathways, there is theoretical interest in how it might complement other interventions that target cellular energy systems.

At PeptidesUK.healthcare we focus on supplying high-purity research peptides for laboratory and investigational use. MOTS-c is an exciting addition to the toolkit for researchers studying mitochondrial function, insulin signaling, skeletal muscle metabolism, or age-related metabolic changes. As with all research compounds, proper handling, storage, and reconstitution are essential to maintain integrity. Researchers typically store the lyophilized peptide at –20 °C and, once reconstituted, keep it refrigerated and use it within recommended timeframes.

Maintaining Perspective

It is important to maintain perspective. MOTS-c remains an investigational compound. No regulatory authority has approved it for human therapeutic use. The current trial is still in its early stages, and many questions about optimal dosing, long-term safety, individual response variability, and potential synergies with other compounds will need to be addressed in future studies. Researchers working with MOTS-c should follow all applicable regulations and institutional guidelines for handling investigational peptides.

The broader story of mitochondrial-derived peptides continues to unfold. MOTS-c is one member of a growing family of signaling molecules produced by mitochondria that influence nuclear gene expression and systemic physiology. This field is expanding our understanding of how cellular energy status communicates with the rest of the body. For those exploring complementary research directions, compounds that support NAD+ levels, methylation balance, or other aspects of mitochondrial health remain active areas of investigation on our site.

We will continue to monitor developments from the NCT07505745 trial and related research. As more peer-reviewed data emerges, we expect to see deeper insights into how MOTS-c and similar mitochondrial signals might fit into comprehensive approaches to metabolic research. In the meantime, the scientific foundation built over the past ten years, combined with this first dedicated human efficacy trial, positions MOTS-c as one of the more interesting peptides to watch in the metabolic and longevity space.

References and Further Reading

• Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. https://pubmed.ncbi.nlm.nih.gov/25738459/

• Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470. https://www.nature.com/articles/s41467-020-20790-0

• ClinicalTrials.gov record NCT07505745: MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. https://clinicaltrials.gov/study/NCT07505745

• Zheng Y, et al. MOTS-c: A promising mitochondrial-derived peptide for metabolic homeostasis and aging. Front Endocrinol. 2023. https://www.frontiersin.org/articles/10.3389/fendo.2023.1120533/full

• Additional mechanistic and human observational studies are available through PubMed searches for "MOTS-c" and "mitochondrial-derived peptide."

For researchers interested in exploring MOTS-c or related mitochondrial support peptides for laboratory use, visit our product pages or contact our team for current specifications and certificates of analysis. Always ensure compliance with local regulations when working with research compounds.

This article is for educational and research purposes only. MOTS-c is a research chemical and is not approved for human therapeutic use. Always adhere to applicable regulations and institutional guidelines when conducting laboratory studies.